Determining the Prognostic Value of the DNA Methylation of the GYPC, NME1, and SLIT2 Genes in Human Lung Adenocarcinoma
ISEF · 2021 Translational Medical Science
Overview
Lung cancer is responsible for the highest number of cancer-related deaths worldwide, and lung adenocarcinoma is its most common subtype. This study used statistical analysis to determine the prognostic value of GYPC, NME1, and SLIT2 DNA methylation for lung adenocarcinoma patients, which could aid in lung adenocarcinoma survival predictions and DNA methylation treatment. ANOVA was used to compare GYPC, NME1, and SLIT2 DNA methylation (as beta values) between tumor and non-tumor tissue and demographic features (age, sex, cancer stage, and smoking history). Kaplan-Meier survival analyses and log-rank tests were utilized to determine CpG sites associated with survival and detect differences in survival across demographic groups and DNA methylation levels of the three target genes. This study found significant differences between tumor and non-tumor methylation for two SLIT2 CpG sites (p = 4.2279e-04 and p = 5.0077e-04) and one GYPC CpG site (p = 1.2376e-04). There was also differential methylation based on cancer stage (p = 0.0228) and smoking history (p = 0.0478) for two SLIT2 CpG sites. Additionally, significant differences were identified in overall survival by cancer stage (p = 0.0133) and the methylation levels of a NME1 CpG site (p = 0.0226) and a GYPC CpG site (p = 0.0379). Lastly, 1426 survival-associated CpG sites were determined. This study achieved its purpose and identified two possible lung adenocarcinoma prognostic biomarkers from the three target genes, along with determining CpG sites that likely play a role in lung adenocarcinoma development and progression due to their differential methylation in tumor tissue.
Competition history
- ISEF 2021
Resources
Related projects
AJAS · 2022
The DNA methylation of SLIT2, GYPC, and NME1 affects lung adenocarcinoma development and progression
CSEF · 2017
Identification of Diagnostic Biomarkers and Therapeutic Targets across Adenocarcinomas Using DNA Methylation Analyses
ISEF · 2021
Identification and Analysis of Key Candidate Genes and Pathways in Lung Adenocarcinoma by Integrated Bioinformatics
AJAS · 2022
Finding and Analyzing New Target Genes for Treatment of Lung Adenocarcinoma using Bioinformatics
ISEF · 2020
A Matter of Life and Breath: Early Lung Cancer Detection via Deep Learning CT Scan Analysis and DNA Methylation/exRNA Sequencing
AJAS · 2025
Investigating Differentially Expressed Genes and Sex-Specific Genes in Lung Cancer
ISEF · 2017
Necrosis of Lung Adenocarcinoma by Targeting a Novel Egg-Specific Protein
ISEF · 2024
Identification of Lung Cancer Biomarkers Through Coding Sequences Targeted by miRNAs
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair